Literature DB >> 10425034

Clinical spectrum of fibroblast growth factor receptor mutations.

M R Passos-Bueno1, W R Wilcox, E W Jabs, A L Sertié, L G Alonso, H Kitoh.   

Abstract

During the last few years, it has been demonstrated that some syndromic craniosynostosis and short-limb dwarfism syndromes, a heterogeneous group comprising of 11 distinct clinical entities, are caused by mutations in one of three fibroblast growth factor receptor genes (FGFR1, FGFR2, and FGFR3). The present review list all mutations described to date in these three genes and the phenotypes associated with them. In addition, the tentative phenotype-genotype correlation is discussed, including the most suggested causative mechanisms for these conditions. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425034     DOI: 10.1002/(SICI)1098-1004(1999)14:2<115::AID-HUMU3>3.0.CO;2-2

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  78 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Echotomography of craniosynostosis: review of literature.

Authors:  Manuela Chiara Accardi; Elena Lo Magno; Santina Ermito; Angela Dinatale; Alessandra Cacciatore; Alessandro Cavaliere; Diego Rossetti
Journal:  J Prenat Med       Date:  2009-04

3.  3-Dimensional morphometric analysis of murine bladder development and dysmorphogenesis.

Authors:  Ashley Carpenter; Andrew Paulus; Melissa Robinson; Carlton M Bates; Michael L Robinson; David Hains; David Kline; Kirk M McHugh
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

Review 4.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

5.  Role of fibroblast growth factor receptor 2 in kidney mesenchyme.

Authors:  David Hains; Sunder Sims-Lucas; Kayle Kish; Monalee Saha; Kirk McHugh; Carlton M Bates
Journal:  Pediatr Res       Date:  2008-12       Impact factor: 3.756

6.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

7.  Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies.

Authors:  Eduard V Bocharov; Dmitry M Lesovoy; Sergey A Goncharuk; Marina V Goncharuk; Kalina Hristova; Alexander S Arseniev
Journal:  Structure       Date:  2013-10-10       Impact factor: 5.006

8.  Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms.

Authors:  Xing Ai; Zhuo-Min Jia; Juan Wang; Gui-Ping DI; X U Zhang; Fengling Sun; Tong Zang; Xiumei Liao
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

9.  Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Petra Jelinkova; Katerina Pejchalova; Alois Kozubik; Leslie Michels Thompson; William R Wilcox
Journal:  Cell Signal       Date:  2008-10-12       Impact factor: 4.315

10.  Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.

Authors:  Zhen Zhen Zhao; Pamela M Pollock; Shane Thomas; Susan A Treloar; Dale R Nyholt; Grant W Montgomery
Journal:  Hum Reprod       Date:  2008-02-18       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.